Effects of Novel E-cigarette Constituents on Adults TCORS 3.0

ConditionNicotine Use Disorder

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorYale University

About this trial

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Eligibility criteria

Qualifiers

18 years or older

Able to read and write

Some current e-cigarette use

Urine cotinine ≥200ng/ml

Disqualifiers

Current use of non-prescription substances besides nicotine, marijuana, alcohol

Any significant current medical or psychiatric condition

Known hypersensitivity to propylene glycol

Pregnant or lactating females

Trial design

Treatments tested in this trial

E-liquid coolant (No WS-3) for non-menthol (1)
E-liquid coolant (No WS-3) for low (0.1%) menthol (1)
E-liquid coolant (No WS-3) for high (2.0%) menthol (1)
E-liquid coolant (Low [0.1%] WS-3) for non-menthol (2)
E-liquid coolant (Low [0.1%] WS-3) for low (0.1%) menthol (2)
E-liquid coolant (Low [0.1%] WS-3) for high (2.0%) menthol (2)
E-liquid coolant (High [2.0%] WS-3) for non-menthol (3)
E-liquid coolant (High [2.0%] WS-3) for low (0.1%) menthol (3)
E-liquid coolant (High [2.0%] WS-3) for high (2.0%) menthol (3)
E-liquid coolant (Low [0.1%] WS-23) for non-menthol (4)
E-liquid coolant (Low [0.1%] WS-23) for low (0.1%) menthol (4)
E-liquid coolant (Low [0.1%] WS-23) for high (2.0%) menthol (4)
E-liquid coolant (High [2.0%] WS-23) for non-menthol (5)
E-liquid coolant (High [2.0%] WS-23) for low (0.1%) menthol (5)
E-liquid coolant (High [2.0%] WS-23) for high (2.0%) menthol (5)
E-liquid coolant (4% WS-23) for non-menthol (6)
E-liquid coolant (4% WS-23) for low (0.1%) menthol (6)
E-liquid coolant (4% WS-23) for high (2.0%) menthol (6)

Treatment groups

66 Participants

are divided into 18 treatment groups

Treatment groups

See each treatment group below.

Sponsors and collaborators

Yale University

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator

Source ClinicalTrials.gov